Grace S Eng, MD
Endocrinology · Emeryville
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Offices
- 2
Offices
2 locations · University Healthcare Alliance · 334 clinicians in this group
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Eng’s office at (925) 462-7060 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A86467 · Current
Licensed to practise in California · since 2004 · expires 2027-10-31 · University of Michigan Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$166,771
Medicare paid this office $166,771 for 413 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 300 | $48,725 | $99 |
| Injection, denosumab, 1 mg | 23 | $29,002 | None |
| Long return visit (40+ min) | 113 | $26,956 | $147 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 343 | $7,892 | $14 |
| New patient visit (45+ min) | 42 | $4,612 | $110 |
See all 10 services
| Return visit (30+ min) | 300 | $48,725 | $99 |
| Injection, denosumab, 1 mg | 23 | $29,002 | None |
| Long return visit (40+ min) | 113 | $26,956 | $147 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 343 | $7,892 | $14 |
| New patient visit (45+ min) | 42 | $4,612 | $110 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 57 | $4,043 | $29 |
| Short return visit (20+ min) | 40 | $2,942 | $68 |
| New patient visit (60+ min) | 11 | $2,017 | $183 |
| Injection of drug or substance under skin or into muscle | 29 | $696 | $14 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $314 | $24 |
Who their Medicare patients are
413 Original Medicare patients in 2024. Average age 75 · Under 65 4% · 85 and older 10% · Women 79% · Also on Medicaid 10% · Health risk score 1.14. At or below the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 62% · Diabetes 35% · Chronic kidney disease 28% · Coronary heart disease 21% · Depression 20% · Atrial fibrillation 18% · Cancer 15% · Heart failure 10% · COPD 10% · Stroke 7% · Dementia 4%.
The office billed $720,908, Medicare allowed $222,231 and paid $166,771; for 7,161 services of 23 kinds; $66,439 of it was for drugs given in the office and $100,332 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 413 | 7,161 | 75 | 1.14 | $720,908 | $166,771 |
| 2023 | 375 | 898 | 75 | 1.22 | $271,842 | $71,304 |
| 2022 | 362 | 842 | 74 | 1.17 | $269,162 | $66,939 |
| 2021 | 320 | 874 | 73 | 1.37 | $328,664 | $73,046 |
| 2020 | 278 | 737 | 73 | 1.44 | $274,068 | $51,004 |
| 2019 | 258 | 544 | 73 | 1.55 | $70,946 | $38,547 |
| 2018 | 221 | 440 | 74 | 1.49 | $52,952 | $30,726 |
| 2017 | 186 | 408 | 73 | 1.50 | $81,645 | $27,655 |
| 2016 | 180 | 560 | 73 | 1.58 | $148,213 | $39,303 |
| 2015 | 170 | 788 | 72 | 1.53 | $178,699 | $50,063 |
| 2014 | 176 | 907 | 72 | 1.41 | $187,916 | $54,380 |
| 2013 | 168 | 959 | 73 | 1.50 | $142,737 | $53,087 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 290 | $35,135 | $79 |
| Long return visit (40+ min) | 123 | $22,597 | $114 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 55 | $4,409 | $29 |
| New patient visit (45+ min) | 33 | $3,594 | $109 |
| New patient visit (60+ min) | 22 | $2,728 | $124 |
| Short return visit (20+ min) | 22 | $1,054 | $46 |
2022: 7 services
| Return visit (30+ min) | 255 | $30,843 | $75 |
| Long return visit (40+ min) | 126 | $22,894 | $119 |
| New patient visit (45+ min) | 41 | $3,685 | $90 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 49 | $3,605 | $29 |
| New patient visit (60+ min) | 23 | $3,581 | $156 |
| Short return visit (20+ min) | 23 | $1,118 | $45 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 11 | $427 | $28 |
2021: 8 services
| Return visit (30+ min) | 234 | $31,108 | $82 |
| Long return visit (40+ min) | 129 | $25,399 | $118 |
| New patient visit (45+ min) | 41 | $4,697 | $115 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 58 | $4,423 | $31 |
| New patient visit (60+ min) | 27 | $3,826 | $142 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,365 | $80 |
| Short return visit (20+ min) | 20 | $1,228 | $56 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | $499 | $29 |
2020: 7 services
| Return visit (30+ min) | 198 | $21,233 | $65 |
| Long return visit (40+ min) | 89 | $14,111 | $93 |
| New patient visit (45+ min) | 49 | $5,024 | $103 |
| Telephone medical discussion with physician, 21-30 minutes | 43 | $4,165 | $72 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 43 | $3,010 | $32 |
| Telephone medical discussion with physician, 11-20 minutes | 16 | $851 | $43 |
| Telehealth originating site facility fee | 11 | $235 | $21 |
2019: 5 services
| Return visit (30+ min) | 202 | $19,301 | $63 |
| Long return visit (40+ min) | 81 | $11,550 | $93 |
| New patient visit (45+ min) | 24 | $2,518 | $105 |
| New patient visit (60+ min) | 15 | $2,261 | $151 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 28 | $1,708 | $32 |
2018: 5 services
| Return visit (30+ min) | 168 | $16,600 | $61 |
| Long return visit (40+ min) | 60 | $6,848 | $93 |
| New patient visit (45+ min) | 37 | $3,195 | $86 |
| New patient visit (60+ min) | 14 | $1,942 | $139 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 12 | $644 | $31 |
2017: 3 services
| Return visit (30+ min) | 141 | $14,490 | $68 |
| Long return visit (40+ min) | 47 | $6,301 | $100 |
| New patient visit (45+ min) | 34 | $3,633 | $107 |
2016: 6 services
| Long return visit (40+ min) | 69 | $16,405 | $116 |
| Return visit (30+ min) | 106 | $12,791 | $83 |
| New patient visit (45+ min) | 22 | $3,203 | $146 |
| Short return visit (20+ min) | 17 | $1,048 | $58 |
| Influenza vaccine split virus, preservative free | 23 | $932 | $41 |
| Administration of influenza virus vaccine | 28 | $868 | $30 |
2015: 6 services
| Long return visit (40+ min) | 81 | $19,436 | $115 |
| Return visit (30+ min) | 123 | $17,501 | $88 |
| New patient visit (45+ min) | 16 | $1,983 | $124 |
| Short return visit (20+ min) | 19 | $1,194 | $60 |
| Administration of influenza virus vaccine | 21 | $631 | $30 |
| Influenza vaccine split virus, preservative free | 17 | $605 | $36 |
2014: 7 services
| Long return visit (40+ min) | 90 | $27,410 | $117 |
| Return visit (30+ min) | 88 | $14,945 | $89 |
| New patient visit (45+ min) | 17 | $2,475 | $146 |
| Short return visit (20+ min) | 14 | $927 | $58 |
| Administration of influenza virus vaccine | 32 | $897 | $28 |
| Influenza vaccine split virus, preservative free | 15 | $491 | $33 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 13 | $215 | $17 |
2013: 4 services
| Long return visit (40+ min) | 74 | $27,486 | $115 |
| Return visit (30+ min) | 92 | $14,546 | $86 |
| Administration of influenza virus vaccine | 30 | $802 | $27 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | 24 | $208 | $9 |
Drugs they prescribed that Part D paid
$1,322,875
Pharmacies billed $1,322,875 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,276 generic and 1,000 brand-name prescriptions · $1,322,875 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Teriparatide | 82 | $274,724 | $3,350 |
| Ozempic | 109 | $215,080 | $1,973 |
| Mounjaro | 68 | $126,004 | $1,853 |
| Trulicity | 50 | $95,246 | $1,905 |
| Jardiance | 53 | $86,630 | $1,635 |
See all 44 drugs
| Teriparatide | 82 | $274,724 | $3,350 |
| Ozempic | 109 | $215,080 | $1,973 |
| Mounjaro | 68 | $126,004 | $1,853 |
| Trulicity | 50 | $95,246 | $1,905 |
| Jardiance | 53 | $86,630 | $1,635 |
| Tymlos | 14 | $62,795 | $4,485 |
| Farxiga | 39 | $56,290 | $1,443 |
| Tradjenta | 30 | $37,674 | $1,256 |
| Rybelsus | 13 | $30,765 | $2,367 |
| Lyumjev | 13 | $24,793 | $1,907 |
| Tresiba Flextouch U-100 | 34 | $19,516 | $574 |
| Januvia | 11 | $18,053 | $1,641 |
| Genotropin | 13 | $12,816 | $986 |
| Tresiba Flextouch U-200 | 18 | $12,518 | $695 |
| Novolog Flexpen | 26 | $10,060 | $387 |
| Lantus Solostar | 60 | $9,597 | $160 |
| Humalog Kwikpen U-100 | 20 | $7,757 | $388 |
| Basaglar Kwikpen U-100 | 17 | $7,615 | $448 |
| Synthroid | 72 | $7,436 | $103 |
| Levothyroxine | 353 | $5,074 | $14 |
| Nano 2nd Gen Pen Needle | 52 | $5,065 | $97 |
| Alendronate | 190 | $4,459 | $23 |
| Metformin Hcl Er | 130 | $2,967 | $23 |
| Ultra-Fine Mini Pen Needle | 23 | $2,462 | $107 |
| Ultra-Fine Nano Pen Needle | 21 | $2,037 | $97 |
| Ultra-Fine Short Pen Needle | 14 | $1,922 | $137 |
| Atorvastatin | 103 | $1,677 | $16 |
| Rosuvastatin | 58 | $1,440 | $25 |
| Valsartan | 11 | $1,410 | $128 |
| Hydrocortisone | 25 | $1,323 | $53 |
| Calcitriol | 20 | $1,138 | $57 |
| Risedronate | 14 | $801 | $57 |
| Methimazole | 47 | $634 | $13 |
| Metformin | 48 | $593 | $12 |
| Levoxyl | 11 | $547 | $50 |
| Glipizide Er | 17 | $468 | $28 |
| Ezetimibe | 17 | $429 | $25 |
| Pioglitazone | 19 | $411 | $22 |
| Losartan | 49 | $403 | $8 |
| Lisinopril | 35 | $233 | $7 |
| Glipizide | 26 | $231 | $9 |
| Chlorthalidone | 12 | $201 | $17 |
| Amlodipine Besylate | 15 | $157 | $10 |
| Hydrochlorothiazide | 18 | $117 | $6 |
Year by year
| 2024 | 2,417 | 323 | None | 41% | $1,322,875 |
| 2023 | 2,402 | 313 | 0% (0) | 45% | $1,546,945 |
| 2022 | 2,305 | 299 | 0% (0) | 41% | $1,372,033 |
| 2021 | 2,276 | 272 | 0% (0) | 42% | $1,119,997 |
| 2020 | 2,213 | 228 | 0% (0) | 42% | $1,047,012 |
| 2019 | 1,773 | 207 | 0% (0) | 42% | $848,387 |
| 2018 | 1,551 | 183 | 0% (0) | 44% | $747,569 |
| 2017 | 1,598 | 177 | 0% (0) | 45% | $578,707 |
| 2016 | 1,813 | 170 | 0% (0) | 41% | $607,252 |
| 2015 | 1,921 | 162 | 0% (0) | 40% | $577,103 |
| 2014 | 1,765 | 148 | 0% (0) | 42% | $360,463 |
| 2013 | 1,880 | 143 | 0% (0) | 43% | $309,844 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 40 drugs
| Ozempic | 120 | $208,347 | $1,736 |
| Trulicity | 91 | $200,955 | $2,208 |
| Teriparatide | 38 | $136,509 | $3,592 |
| Forteo | 22 | $106,324 | $4,833 |
| Mounjaro | 57 | $102,253 | $1,794 |
| Farxiga | 58 | $91,520 | $1,578 |
| Jardiance | 59 | $90,689 | $1,537 |
| Novolog Flexpen | 39 | $56,137 | $1,439 |
| Lantus Solostar | 81 | $51,430 | $635 |
| Tradjenta | 27 | $37,761 | $1,399 |
| Humalog Kwikpen U-100 | 25 | $32,954 | $1,318 |
| Rybelsus | 15 | $29,372 | $1,958 |
| Invokana | 16 | $29,259 | $1,829 |
| Genotropin | 25 | $28,858 | $1,154 |
| Januvia | 15 | $24,261 | $1,617 |
| Tresiba Flextouch U-100 | 35 | $23,499 | $671 |
| Humalog | 13 | $20,236 | $1,557 |
| Synthroid | 62 | $8,246 | $133 |
| Baqsimi | 11 | $6,051 | $550 |
| Levothyroxine | 311 | $5,783 | $19 |
| Alendronate | 156 | $4,708 | $30 |
| Ultra-Fine Nano Pen Needle | 30 | $4,060 | $135 |
| Nano 2nd Gen Pen Needle | 44 | $3,670 | $83 |
| Rosuvastatin | 62 | $3,313 | $53 |
| Metformin Hcl Er | 121 | $2,950 | $24 |
| Atorvastatin | 115 | $2,075 | $18 |
| Ultra-Fine Mini Pen Needle | 16 | $2,051 | $128 |
| Hydrocortisone | 20 | $1,732 | $87 |
| Pioglitazone | 15 | $1,518 | $101 |
| Calcitriol | 20 | $1,330 | $66 |
| Glipizide Er | 14 | $990 | $71 |
| Metformin | 57 | $812 | $14 |
| Methimazole | 45 | $801 | $18 |
| Lisinopril | 50 | $488 | $10 |
| Losartan | 39 | $433 | $11 |
| Ezetimibe | 13 | $326 | $25 |
| Glipizide | 22 | $277 | $13 |
| Amlodipine Besylate | 24 | $228 | $9 |
| Levoxyl | 12 | $143 | $12 |
| Hydrochlorothiazide | 14 | $66 | $5 |
2022: 42 drugs
| Ozempic | 116 | $217,997 | $1,879 |
| Trulicity | 81 | $164,624 | $2,032 |
| Tymlos | 27 | $112,943 | $4,183 |
| Forteo | 16 | $92,518 | $5,782 |
| Novolog Flexpen | 44 | $92,299 | $2,098 |
| Jardiance | 50 | $84,521 | $1,690 |
| Farxiga | 52 | $73,908 | $1,421 |
| Lantus Solostar | 87 | $55,390 | $637 |
| Teriparatide | 14 | $45,215 | $3,230 |
| Mounjaro | 20 | $39,417 | $1,971 |
| Januvia | 29 | $37,821 | $1,304 |
| Humalog Kwikpen U-100 | 16 | $28,750 | $1,797 |
| Tradjenta | 19 | $24,605 | $1,295 |
| Humalog | 23 | $23,993 | $1,043 |
| Tresiba Flextouch U-100 | 33 | $23,573 | $714 |
| Invokana | 11 | $19,944 | $1,813 |
| Genotropin | 13 | $11,361 | $874 |
| Levothyroxine | 301 | $6,187 | $21 |
| Synthroid | 49 | $6,048 | $123 |
| Nano 2nd Gen Pen Needle | 39 | $4,736 | $121 |
| Alendronate | 113 | $4,597 | $41 |
| Basaglar Kwikpen U-100 | 11 | $4,572 | $416 |
| Ultra-Fine Nano Pen Needle | 38 | $3,676 | $97 |
| Metformin Hcl Er | 151 | $3,249 | $22 |
| Ultra-Fine Short Pen Needle | 12 | $2,509 | $209 |
| Rosuvastatin | 41 | $2,064 | $50 |
| Atorvastatin | 134 | $1,843 | $14 |
| Hydrocortisone | 20 | $1,237 | $62 |
| Pioglitazone | 22 | $1,228 | $56 |
| Fenofibrate | 12 | $1,050 | $87 |
| Calcitriol | 20 | $1,008 | $50 |
| Easy Comfort Insulin | 11 | $909 | $83 |
| Metformin | 57 | $881 | $15 |
| Glipizide Er | 13 | $614 | $47 |
| Methimazole | 46 | $610 | $13 |
| Losartan | 47 | $541 | $12 |
| Lisinopril | 49 | $502 | $10 |
| Amlodipine Besylate | 44 | $488 | $11 |
| Easy Touch Pen Needle | 12 | $429 | $36 |
| Hydrochlorothiazide | 21 | $273 | $13 |
| Carvedilol | 14 | $182 | $13 |
| Glipizide | 20 | $177 | $9 |
2021: 41 drugs
| Ozempic | 110 | $196,030 | $1,782 |
| Trulicity | 77 | $116,871 | $1,518 |
| Novolog Flexpen | 57 | $101,209 | $1,776 |
| Tymlos | 37 | $92,897 | $2,511 |
| Lantus Solostar | 99 | $62,701 | $633 |
| Jardiance | 49 | $61,175 | $1,248 |
| Farxiga | 36 | $54,634 | $1,518 |
| Humalog Kwikpen U-100 | 22 | $37,814 | $1,719 |
| Januvia | 25 | $31,863 | $1,275 |
| Humalog | 31 | $30,899 | $997 |
| Tresiba Flextouch U-100 | 31 | $21,978 | $709 |
| Tradjenta | 12 | $15,342 | $1,279 |
| Novolog Mix 70-30 Flexpen | 11 | $13,710 | $1,246 |
| Genotropin | 14 | $11,912 | $851 |
| Synthroid | 54 | $7,048 | $131 |
| Levothyroxine | 269 | $6,546 | $24 |
| Onglyza | 11 | $5,350 | $486 |
| Nano 2nd Gen Pen Needle | 26 | $3,135 | $121 |
| Ultra-Fine Nano Pen Needle | 41 | $2,987 | $73 |
| Ultra-Fine Mini Pen Needle | 22 | $2,983 | $136 |
| Metformin Hcl Er | 135 | $2,732 | $20 |
| Ultra-Fine Short Pen Needle | 11 | $2,010 | $183 |
| Rosuvastatin | 39 | $1,929 | $49 |
| Atorvastatin | 149 | $1,921 | $13 |
| Fenofibrate | 17 | $1,456 | $86 |
| Hydrocortisone | 20 | $1,242 | $62 |
| Metformin | 63 | $969 | $15 |
| Pioglitazone | 28 | $907 | $32 |
| Glipizide | 49 | $769 | $16 |
| Calcitriol | 13 | $726 | $56 |
| Alendronate | 59 | $724 | $12 |
| Losartan | 40 | $592 | $15 |
| Methimazole | 40 | $569 | $14 |
| Amlodipine Besylate | 59 | $517 | $9 |
| Lisinopril | 62 | $493 | $8 |
| Glipizide Er | 14 | $398 | $28 |
| Losartan-Hydrochlorothiazide | 12 | $337 | $28 |
| Carvedilol | 24 | $328 | $14 |
| Atenolol | 14 | $128 | $9 |
| Glimepiride | 13 | $96 | $7 |
| Hydrochlorothiazide | 16 | $96 | $6 |
2020: 43 drugs
| Forteo | 17 | $115,028 | $6,766 |
| Novolog Flexpen | 71 | $109,625 | $1,544 |
| Trulicity | 68 | $90,448 | $1,330 |
| Ozempic | 37 | $80,616 | $2,179 |
| Glumetza | 11 | $70,276 | $6,389 |
| Lantus Solostar | 109 | $67,475 | $619 |
| Victoza 3-Pak | 30 | $54,106 | $1,804 |
| Humalog | 41 | $48,831 | $1,191 |
| Humalog Kwikpen U-100 | 27 | $41,605 | $1,541 |
| Januvia | 30 | $35,796 | $1,193 |
| Jardiance | 25 | $22,801 | $912 |
| Tresiba Flextouch U-100 | 43 | $22,618 | $526 |
| Genotropin | 14 | $12,064 | $862 |
| Novolog Mix 70-30 Flexpen | 16 | $11,128 | $695 |
| Levothyroxine | 241 | $6,124 | $25 |
| Synthroid | 56 | $5,963 | $106 |
| Ultra-Fine Nano Pen Needle | 61 | $5,955 | $98 |
| Onglyza | 13 | $5,935 | $457 |
| Humulin 70-30 | 14 | $4,204 | $300 |
| Metformin Hcl Er | 115 | $2,818 | $25 |
| Atorvastatin | 133 | $2,601 | $20 |
| Rosuvastatin | 52 | $2,580 | $50 |
| Ultra-Fine Mini Pen Needle | 19 | $2,196 | $116 |
| Fenofibrate | 21 | $1,967 | $94 |
| Ultra-Fine Short Pen Needle | 14 | $1,478 | $106 |
| Nano 2nd Gen Pen Needle | 12 | $1,381 | $115 |
| Pioglitazone | 29 | $1,224 | $42 |
| Hydrocortisone | 23 | $1,172 | $51 |
| Liothyronine | 16 | $975 | $61 |
| Alendronate | 62 | $960 | $15 |
| Glipizide | 61 | $909 | $15 |
| Metformin | 51 | $739 | $14 |
| Metoprolol | 13 | $595 | $46 |
| Losartan | 32 | $582 | $18 |
| Lisinopril | 79 | $579 | $7 |
| Glipizide Er | 16 | $467 | $29 |
| Pravastatin | 15 | $455 | $30 |
| Amlodipine Besylate | 55 | $420 | $8 |
| Methimazole | 25 | $374 | $15 |
| Carvedilol | 32 | $372 | $12 |
| Simvastatin | 14 | $296 | $21 |
| Losartan-Hydrochlorothiazide | 14 | $286 | $20 |
| Hydrochlorothiazide | 17 | $100 | $6 |
2019: 41 drugs
| Forteo | 34 | $208,839 | $6,142 |
| Novolog Flexpen | 53 | $87,379 | $1,649 |
| Victoza 3-Pak | 45 | $70,291 | $1,562 |
| Lantus Solostar | 92 | $53,934 | $586 |
| Januvia | 37 | $46,309 | $1,252 |
| Trulicity | 28 | $39,251 | $1,402 |
| Humalog Kwikpen U-100 | 31 | $35,847 | $1,156 |
| Humalog | 30 | $32,195 | $1,073 |
| Ozempic | 20 | $32,013 | $1,601 |
| Tradjenta | 14 | $15,584 | $1,113 |
| Lantus | 12 | $13,504 | $1,125 |
| Jardiance | 15 | $9,669 | $645 |
| Novolog Mix 70-30 Flexpen | 17 | $9,351 | $550 |
| Tresiba Flextouch U-100 | 13 | $6,383 | $491 |
| Onglyza | 12 | $5,277 | $440 |
| Ultra-Fine Nano Pen Needle | 50 | $5,197 | $104 |
| Levothyroxine | 168 | $4,478 | $27 |
| Tirosint | 16 | $3,916 | $245 |
| Rosuvastatin | 43 | $3,452 | $80 |
| Synthroid | 36 | $2,953 | $82 |
| Atorvastatin | 87 | $2,349 | $27 |
| Metformin Hcl Er | 108 | $2,349 | $22 |
| Ultra-Fine Mini Pen Needle | 25 | $1,930 | $77 |
| Ultra-Fine Short Pen Needle | 12 | $1,164 | $97 |
| Metoprolol | 15 | $1,067 | $71 |
| Pioglitazone | 26 | $1,006 | $39 |
| Fenofibrate | 15 | $940 | $63 |
| Hydrocortisone | 11 | $778 | $71 |
| Metformin | 57 | $663 | $12 |
| Glipizide | 60 | $626 | $10 |
| Methimazole | 20 | $568 | $28 |
| Glipizide Er | 14 | $515 | $37 |
| Alendronate | 32 | $492 | $15 |
| Lisinopril | 59 | $394 | $7 |
| Testosterone Cypionate | 11 | $383 | $35 |
| Amlodipine Besylate | 49 | $337 | $7 |
| Losartan | 21 | $302 | $14 |
| Glimepiride | 14 | $280 | $20 |
| Losartan-Hydrochlorothiazide | 12 | $271 | $23 |
| Carvedilol | 15 | $236 | $16 |
| Hydrochlorothiazide | 11 | $56 | $5 |
2018: 35 drugs
| Forteo | 42 | $252,520 | $6,012 |
| Novolog Flexpen | 30 | $60,726 | $2,024 |
| Lantus Solostar | 70 | $43,258 | $618 |
| Victoza 3-Pak | 25 | $39,645 | $1,586 |
| Humalog Kwikpen U-100 | 36 | $36,435 | $1,012 |
| Humalog | 36 | $36,291 | $1,008 |
| Januvia | 33 | $28,237 | $856 |
| Trulicity | 20 | $23,634 | $1,182 |
| Lantus | 31 | $22,734 | $733 |
| Invokana | 20 | $17,178 | $859 |
| Genotropin | 12 | $11,425 | $952 |
| Humalog Mix 75-25 Kwikpen | 11 | $7,786 | $708 |
| Novolog Mix 70-30 Flexpen | 14 | $7,520 | $537 |
| Onglyza | 12 | $5,116 | $426 |
| Ultra-Fine Nano Pen Needle | 54 | $5,109 | $95 |
| Levothyroxine | 154 | $3,718 | $24 |
| Tirosint | 28 | $3,609 | $129 |
| Rosuvastatin | 30 | $3,019 | $101 |
| Synthroid | 44 | $2,792 | $63 |
| Ultra-Fine Mini Pen Needle | 19 | $2,023 | $106 |
| Atorvastatin | 87 | $1,741 | $20 |
| Metformin Hcl Er | 77 | $1,295 | $17 |
| Pravastatin | 18 | $926 | $51 |
| Pioglitazone | 27 | $781 | $29 |
| Ezetimibe | 11 | $614 | $56 |
| Glipizide | 60 | $596 | $10 |
| Metformin | 52 | $590 | $11 |
| Alendronate | 38 | $524 | $14 |
| Metoprolol | 11 | $415 | $38 |
| Methimazole | 17 | $340 | $20 |
| Lisinopril | 46 | $304 | $7 |
| Amlodipine Besylate | 35 | $251 | $7 |
| Glimepiride | 11 | $190 | $17 |
| Losartan | 25 | $146 | $6 |
| Ramipril | 11 | $103 | $9 |
2017: 40 drugs
| Forteo | 28 | $102,507 | $3,661 |
| Lantus Solostar | 97 | $73,046 | $753 |
| Novolog Flexpen | 36 | $59,561 | $1,654 |
| Victoza 3-Pak | 35 | $46,923 | $1,341 |
| Humalog Kwikpen U-100 | 44 | $37,921 | $862 |
| Humalog | 46 | $33,266 | $723 |
| Januvia | 28 | $26,057 | $931 |
| Invokana | 25 | $19,053 | $762 |
| Lantus | 22 | $14,992 | $681 |
| Novolog Mix 70-30 Flexpen | 18 | $14,229 | $791 |
| Trulicity | 12 | $12,078 | $1,007 |
| Tradjenta | 18 | $11,765 | $654 |
| Genotropin | 12 | $9,073 | $756 |
| Onglyza | 13 | $4,666 | $359 |
| Ultra-Fine Nano Pen Needle | 45 | $4,443 | $99 |
| Synthroid | 77 | $3,678 | $48 |
| Levothyroxine | 143 | $3,647 | $26 |
| Novolog | 12 | $3,379 | $282 |
| Atorvastatin | 91 | $2,433 | $27 |
| Tirosint | 14 | $2,311 | $165 |
| Bd Ultra-Fine Pen Needle | 23 | $2,097 | $91 |
| Calcitriol | 11 | $2,090 | $190 |
| Raloxifene | 11 | $1,904 | $173 |
| Pioglitazone | 42 | $1,367 | $33 |
| Ultra-Fine Mini Pen Needle | 18 | $1,290 | $72 |
| Metformin Hcl Er | 60 | $1,145 | $19 |
| Insulin | 25 | $1,141 | $46 |
| Pravastatin | 14 | $744 | $53 |
| Rosuvastatin | 16 | $657 | $41 |
| Gabapentin | 15 | $581 | $39 |
| Valsartan | 17 | $567 | $33 |
| Glipizide | 73 | $549 | $8 |
| Metformin | 56 | $509 | $9 |
| Alendronate | 31 | $357 | $12 |
| Lisinopril | 43 | $282 | $7 |
| Methimazole | 13 | $265 | $20 |
| Carvedilol | 24 | $232 | $10 |
| Amlodipine Besylate | 24 | $170 | $7 |
| Simvastatin | 16 | $156 | $10 |
| Ramipril | 14 | $146 | $10 |
2016: 43 drugs
| Forteo | 43 | $130,883 | $3,044 |
| Lantus Solostar | 106 | $69,851 | $659 |
| Novolog Flexpen | 42 | $56,990 | $1,357 |
| Humalog Kwikpen U-100 | 40 | $42,888 | $1,072 |
| Januvia | 46 | $36,618 | $796 |
| Humalog | 41 | $31,863 | $777 |
| Novolog Mix 70-30 Flexpen | 27 | $22,569 | $836 |
| Lantus | 32 | $19,574 | $612 |
| Invokana | 26 | $19,099 | $735 |
| Tradjenta | 25 | $15,255 | $610 |
| Victoza 3-Pak | 14 | $14,380 | $1,027 |
| Bd Ultra-Fine Pen Needle | 137 | $10,582 | $77 |
| Novolog | 17 | $8,693 | $511 |
| Humalog Mix 75-25 Kwikpen | 14 | $8,000 | $571 |
| Crestor | 18 | $7,434 | $413 |
| Onglyza | 11 | $4,699 | $427 |
| Raloxifene | 13 | $3,966 | $305 |
| Zetia | 13 | $3,959 | $305 |
| Levothyroxine | 127 | $3,265 | $26 |
| Synthroid | 63 | $3,085 | $49 |
| Rosuvastatin | 15 | $2,842 | $189 |
| Atorvastatin | 85 | $2,372 | $28 |
| Calcitriol | 14 | $2,287 | $163 |
| Tirosint | 14 | $1,514 | $108 |
| Valsartan | 27 | $1,335 | $49 |
| Pioglitazone | 49 | $1,136 | $23 |
| Metformin | 86 | $1,061 | $12 |
| Insulin | 27 | $1,051 | $39 |
| Repaglinide | 12 | $997 | $83 |
| Glipizide | 97 | $907 | $9 |
| Metformin Hcl Er | 57 | $769 | $13 |
| Pravastatin | 18 | $716 | $40 |
| Losartan-Hydrochlorothiazide | 12 | $511 | $43 |
| Gabapentin | 22 | $478 | $22 |
| Methimazole | 44 | $422 | $10 |
| Lisinopril | 51 | $298 | $6 |
| Simvastatin | 25 | $289 | $12 |
| Alendronate | 22 | $201 | $9 |
| Amlodipine Besylate | 20 | $198 | $10 |
| Atenolol | 12 | $145 | $12 |
| Carvedilol | 19 | $131 | $7 |
| Losartan | 18 | $96 | $5 |
| Hydrochlorothiazide | 11 | $48 | $4 |
2015: 46 drugs
| Lantus Solostar | 113 | $63,508 | $562 |
| Forteo | 19 | $62,133 | $3,270 |
| Novolog Flexpen | 42 | $48,159 | $1,147 |
| Januvia | 53 | $35,136 | $663 |
| Humalog Kwikpen U-100 | 43 | $30,191 | $702 |
| Humalog | 30 | $28,590 | $953 |
| Novolog Mix 70-30 Flexpen | 37 | $26,515 | $717 |
| Novolog | 31 | $19,693 | $635 |
| Apidra | 14 | $19,446 | $1,389 |
| Lantus | 35 | $18,951 | $541 |
| Victoza 3-Pak | 14 | $11,652 | $832 |
| Crestor | 35 | $11,236 | $321 |
| Tradjenta | 27 | $10,384 | $385 |
| Bd Ultra-Fine Pen Needle | 128 | $9,415 | $74 |
| Invokana | 18 | $7,993 | $444 |
| Onglyza | 14 | $5,899 | $421 |
| Welchol | 12 | $5,844 | $487 |
| Raloxifene | 14 | $5,074 | $362 |
| Levothyroxine | 177 | $4,338 | $25 |
| Repaglinide | 26 | $4,210 | $162 |
| Synthroid | 61 | $2,731 | $45 |
| Pioglitazone | 53 | $2,473 | $47 |
| Valsartan | 23 | $2,075 | $90 |
| Niacin Er | 11 | $1,996 | $181 |
| Atorvastatin | 47 | $1,375 | $29 |
| Insulin | 33 | $1,199 | $36 |
| Pravastatin | 62 | $1,147 | $19 |
| Metformin Hcl Er | 52 | $1,134 | $22 |
| Glipizide | 102 | $925 | $9 |
| Metformin | 66 | $789 | $12 |
| Methimazole | 37 | $565 | $15 |
| Quinapril | 12 | $431 | $36 |
| Prednisone | 11 | $371 | $34 |
| Lisinopril | 44 | $327 | $7 |
| Hydrocortisone | 11 | $261 | $24 |
| Alendronate | 24 | $246 | $10 |
| Losartan | 34 | $235 | $7 |
| Gabapentin | 18 | $229 | $13 |
| Simvastatin | 22 | $204 | $9 |
| Amlodipine Besylate | 21 | $181 | $9 |
| Atenolol | 28 | $157 | $6 |
| Lovastatin | 13 | $138 | $11 |
| Carvedilol | 13 | $106 | $8 |
| Hydrochlorothiazide | 35 | $101 | $3 |
| Glimepiride | 12 | $95 | $8 |
| Ramipril | 12 | $66 | $6 |
2014: 34 drugs
| Humalog | 89 | $49,236 | $553 |
| Lantus Solostar | 99 | $40,408 | $408 |
| Novolog Flexpen | 49 | $33,049 | $674 |
| Januvia | 49 | $30,699 | $627 |
| Novolog Mix 70-30 Flexpen | 35 | $23,474 | $671 |
| Lantus | 52 | $21,556 | $415 |
| Apidra | 12 | $14,446 | $1,204 |
| Novolog | 12 | $11,294 | $941 |
| Crestor | 32 | $8,744 | $273 |
| Bd Ultra-Fine Pen Needle | 132 | $8,515 | $65 |
| Victoza 3-Pak | 14 | $8,025 | $573 |
| Repaglinide | 26 | $5,527 | $213 |
| Levothyroxine | 205 | $3,763 | $18 |
| Pioglitazone | 53 | $3,017 | $57 |
| Synthroid | 68 | $2,442 | $36 |
| Fenofibrate | 14 | $1,206 | $86 |
| Metformin | 57 | $938 | $16 |
| Pravastatin | 50 | $838 | $17 |
| Metformin Hcl Er | 45 | $809 | $18 |
| Atorvastatin | 42 | $754 | $18 |
| Glipizide | 59 | $726 | $12 |
| Insulin | 13 | $579 | $45 |
| Quinapril | 12 | $545 | $45 |
| Methimazole | 32 | $491 | $15 |
| Gabapentin | 19 | $467 | $25 |
| Simvastatin | 52 | $427 | $8 |
| Glyburide | 15 | $329 | $22 |
| Losartan | 20 | $326 | $16 |
| Lisinopril | 47 | $274 | $6 |
| Alendronate | 31 | $242 | $8 |
| Lovastatin | 13 | $205 | $16 |
| Amlodipine Besylate | 17 | $152 | $9 |
| Hydrochlorothiazide | 29 | $142 | $5 |
| Atenolol | 17 | $120 | $7 |
2013: 45 drugs
| Novolog Flexpen | 72 | $30,471 | $423 |
| Lantus Solostar | 95 | $30,450 | $321 |
| Humalog | 66 | $28,716 | $435 |
| Januvia | 57 | $27,555 | $483 |
| Novolog Mix 70-30 Flexpen | 35 | $19,671 | $562 |
| Lantus | 57 | $16,018 | $281 |
| Byetta | 27 | $12,166 | $451 |
| Symlinpen 120 | 11 | $11,348 | $1,032 |
| Victoza 3-Pak | 18 | $11,289 | $627 |
| Apidra | 14 | $11,049 | $789 |
| Novolog | 19 | $9,914 | $522 |
| Bd Ultra-Fine Pen Needle | 152 | $8,267 | $54 |
| Pioglitazone | 41 | $5,734 | $140 |
| Prandin | 15 | $5,609 | $374 |
| Crestor | 17 | $4,571 | $269 |
| Humulin R | 11 | $3,462 | $315 |
| Evista | 12 | $3,412 | $284 |
| Benicar | 17 | $2,660 | $156 |
| Fenofibrate | 27 | $2,277 | $84 |
| Metformin Hcl Er | 29 | $2,106 | $73 |
| Levothyroxine | 175 | $2,101 | $12 |
| Synthroid | 50 | $1,613 | $32 |
| Metformin | 93 | $1,508 | $16 |
| Atorvastatin | 44 | $1,395 | $32 |
| Glyburide | 40 | $1,045 | $26 |
| Insulin | 17 | $851 | $50 |
| Pravastatin | 58 | $848 | $15 |
| Glipizide | 59 | $736 | $12 |
| Gabapentin | 26 | $734 | $28 |
| Methimazole | 41 | $717 | $17 |
| Losartan | 40 | $668 | $17 |
| Lovastatin | 31 | $639 | $21 |
| Simvastatin | 59 | $626 | $11 |
| Insulin | 17 | $586 | $34 |
| Glipizide Xl | 12 | $554 | $46 |
| Propylthiouracil | 12 | $540 | $45 |
| Hydralazine | 11 | $327 | $30 |
| Lisinopril | 43 | $290 | $7 |
| Quinapril | 12 | $282 | $23 |
| Alendronate | 25 | $271 | $11 |
| Amlodipine Besylate | 28 | $261 | $9 |
| Prednisone | 11 | $170 | $15 |
| Atenolol | 12 | $147 | $12 |
| Carvedilol | 13 | $104 | $8 |
| Hydrochlorothiazide | 26 | $90 | $3 |
Professional record
- NPI
- 1871552679
- Licence
- CA A86467California A86467: Current · expires 2027-10-31
- Trained
- University of Michigan Medical School, 1999
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X); Internal medicine (207R00000X)
- Mailing address
- 5800 Hollis St, Emeryville, CA, 94608
- NPI first listed
- 2006-03-21
- NPI last updated
- 2024-04-29
- NPI record certified
- 2024-04-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Palo Alto, CA, 94304